BIOMAT Database Logo BIOMAT Database Logo

Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. 1991

L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Clinica Neurologica IV, IRCCS San Raffaele, Milano, Italy.

To assess the role of alpha-tumor necrosis factor in the pathogenesis of central nervous system involvement during human immunodeficiency virus type 1 infection, we recorded clinical data and measured alpha-tumor necrosis factor levels in serum and cerebrospinal fluid samples from 45 patients infected with human immunodeficiency virus type 1, classified as group II/III (10), group IV A (5), group IV B (10), and group IV C-1 (20) of the Centers for Disease Control acquired immunodeficiency syndrome classification system and 42 controls. Alpha-tumor necrosis factor was above the limit of detection in only 3 of 15 sera and 3 of 15 cerebrospinal fluid samples from patients in group II/III and group IV A, whereas it was detected in 17 of 30 sera (p less than 0.05) and 22 of 30 cerebrospinal fluid (p less than 0.0002) samples from clinically more advanced patients (group IV B and group IV C-1). Alpha-tumor necrosis factor mean values were 21.5 pg/ml in sera and 50.0 pg/ml in cerebrospinal fluid from group IV B patients and 30.4 pg/ml in sera and 24 pg/ml in cerebrospinal fluid from group IV C-1 patients.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003711 Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system. Clinically Isolated CNS Demyelinating Syndrome,Clinically Isolated Syndrome, CNS Demyelinating,Demyelinating Disorders,Demyelination,Demyelinating Disease,Demyelinating Disorder,Demyelinations
D005260 Female Females
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Undetectable tumor necrosis factor-alpha in spinal fluid from HIV-1-infected patients.
June 1992, Annals of neurology,
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
[Alpha tumor necrosis factor in central nervous system disease associated with HIV infection].
June 1995, Anales de medicina interna (Madrid, Spain : 1984),
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1-Infected Patients with Central Nervous System Impairment.
June 2019, Open forum infectious diseases,
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Elevated levels of tumor necrosis factor (TNF) in the cerebrospinal fluid from patients with HIV-associated neurological disorders.
February 1990, Acta neurologica,
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement.
May 1990, Arthritis and rheumatism,
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Elevated levels of circulating intercellular adhesion molecule 1 and tumor necrosis factor alpha in the serum of children vertically infected with HIV-1.
December 1996, Pediatric AIDS and HIV infection,
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Cerebrospinal fluid interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with central nervous system infections.
January 1996, Zhonghua Minguo xiao er ke yi xue hui za zhi [Journal]. Zhonghua Minguo xiao er ke yi xue hui,
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
[Tumor necrosis factor and central nervous system].
January 1998, Sheng li ke xue jin zhan [Progress in physiology],
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Tumor necrosis factor in the cerebrospinal fluid of children with central nervous system leukemia.
January 1991, Leukemia research,
L M Grimaldi, and G V Martino, and D M Franciotta, and R Brustia, and A Castagna, and R Pristerà, and A Lazzarin
Elevated levels of plasma tumor necrosis factor alpha in patients with pseudoexfoliation glaucoma.
January 2018, Clinical ophthalmology (Auckland, N.Z.),
Copied contents to your clipboard!